+

CO2024012022A2 - Conjugados anticuerpo-fármaco y sus usos - Google Patents

Conjugados anticuerpo-fármaco y sus usos

Info

Publication number
CO2024012022A2
CO2024012022A2 CONC2024/0012022A CO2024012022A CO2024012022A2 CO 2024012022 A2 CO2024012022 A2 CO 2024012022A2 CO 2024012022 A CO2024012022 A CO 2024012022A CO 2024012022 A2 CO2024012022 A2 CO 2024012022A2
Authority
CO
Colombia
Prior art keywords
antibody
drug conjugates
drug
conjugates
cancers
Prior art date
Application number
CONC2024/0012022A
Other languages
English (en)
Inventor
Warren Viricel
Original Assignee
Mablink Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mablink Bioscience filed Critical Mablink Bioscience
Publication of CO2024012022A2 publication Critical patent/CO2024012022A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con conjugados anticuerpo-fármaco, en donde el anticuerpo se une específicamente al receptor alfa de folato, y en donde el fármaco se selecciona referentemente entre un fármaco citotóxico. Tales conjugados anticuerpofármaco son útiles en particular en el tratamiento de enfermedades proliferativas que incluyen cánceres, tales como cánceres de ovario, de mama y de pulmón de células no pequeñas
CONC2024/0012022A 2022-03-11 2024-09-03 Conjugados anticuerpo-fármaco y sus usos CO2024012022A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305279 2022-03-11
PCT/EP2023/056097 WO2023170247A1 (en) 2022-03-11 2023-03-10 Antibody-drug conjugates and their uses

Publications (1)

Publication Number Publication Date
CO2024012022A2 true CO2024012022A2 (es) 2024-09-19

Family

ID=80979142

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0012022A CO2024012022A2 (es) 2022-03-11 2024-09-03 Conjugados anticuerpo-fármaco y sus usos

Country Status (14)

Country Link
US (1) US20250302978A1 (es)
EP (1) EP4489788A1 (es)
JP (1) JP7706668B2 (es)
KR (1) KR20240168351A (es)
CN (1) CN119173279A (es)
AU (1) AU2023231442A1 (es)
CL (1) CL2024002655A1 (es)
CO (1) CO2024012022A2 (es)
CR (1) CR20240375A (es)
DO (1) DOP2024000178A (es)
IL (1) IL314828A (es)
MX (1) MX2024011013A (es)
PE (1) PE20251386A1 (es)
WO (1) WO2023170247A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534101A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
PE20231049A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
IL272964B2 (en) 2017-08-31 2024-02-01 Daiichi Sankyo Co Ltd Method for producing antibody-drug conjugate
WO2019055931A1 (en) * 2017-09-18 2019-03-21 Sutro Biopharma, Inc. ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
US20200345863A1 (en) 2017-10-23 2020-11-05 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
EP4032892A4 (en) * 2019-09-18 2023-10-18 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin derivative and conjugate thereof
CA3215279A1 (en) * 2021-03-30 2022-10-06 Mablink Bioscience Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties

Also Published As

Publication number Publication date
CN119173279A (zh) 2024-12-20
JP7706668B2 (ja) 2025-07-11
EP4489788A1 (en) 2025-01-15
AU2023231442A1 (en) 2024-09-26
CL2024002655A1 (es) 2025-05-23
KR20240168351A (ko) 2024-11-29
DOP2024000178A (es) 2024-11-29
CR20240375A (es) 2025-01-06
MX2024011013A (es) 2024-09-17
US20250302978A1 (en) 2025-10-02
WO2023170247A1 (en) 2023-09-14
JP2025509142A (ja) 2025-04-11
PE20251386A1 (es) 2025-05-22
IL314828A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
CO2024012022A2 (es) Conjugados anticuerpo-fármaco y sus usos
MX2020010408A (es) Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer.
JOP20210073A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
MX2023005645A (es) Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
CY1119324T1 (el) Αντισωματα εναντιον csf-1r
CO2022001316A2 (es) Conjugados peptídicos de citotoxinas como terapéuticos
PE20090245A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
EA200701250A1 (ru) Иммуноконъюгаты против интегрина, способы и варианты применения
UY35712A (es) Anticuerpos anti-prlr y uso de los mismos
DOP2011000331A (es) Inmunoconjugados de antimesotelina y usos de los mismos
UY33591A (es) Nuevas proteínas de unión a antígenos
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.
ECSP22010121A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
MX2020011487A (es) Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
CO2025000513A2 (es) Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1 y métodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1
CO2025004991A2 (es) Anticuerpo anti-gucy2c y usos del mismo
CO6690754A2 (es) Composiciones de anticuerpo anti-vegfr-3
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
MX2024012413A (es) Conjugados de anticuerpo-farmaco basados en eribulina y metodos de uso
MX2023008426A (es) Polipeptidos variantes de actinohivina y metodos relacionados.
MX2025005210A (es) Anticuerpos anti-avb6 y conjugados anticuerpo-fármaco y su uso en el tratamiento del cáncer
AR132465A1 (es) Anticuerpos lilrb1 y lilrb2 y métodos de uso de estos
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载